Advertisement

BMC Cancer

, 18:1288 | Cite as

Correction to: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases

  • Wan-Ling Tan
  • Quan Sing Ng
  • Cindy Lim
  • Eng Huat Tan
  • Chee Keong Toh
  • Mei-Kim Ang
  • Ravindran Kanesvaran
  • Amit Jain
  • Daniel S. W. Tan
  • Darren Wan-Teck LimEmail author
Open Access
Correction
  • 208 Downloads

Correction to: BMC Cancer (2018) 18:1198

DOI: 10.1186/s12885-018-5110-2

Following publication of the original article [1], the authors notified us of a typographical error in Table 1.
Table 1

Patient Baseline Characteristics. The baseline demographics and clinical characteristics of patients with advanced EGFRm + NSCLC treated with first-line afatinib (n = 125) in our cohort

Characteristic

No.

%

Sex

 Male

64

51.2

 Female

61

48.8

Age at diagnosis, years

 Median

62

 

 Range

26–86

 

Ethnicity

 Chinese

100

80.0

 Malay

14

11.2

 Indian

3

2.4

 Others

8

6.4

Smoking status

 Never

95

76.0

 Former

17

13.6

 Current

13

10.4

Histotype – NSCLC

 Adenocarcinoma

121

96.8

 Adenosquamous carcinoma

1

0.8

 NOS

3

2.4

EGFR mutation type

 Exon 19 deletion[a]

87

69.6

 Exon 21 L858R

27

21.6

 Others[b]

11

8.8

Brain metastases at baseline

 No

82

65.6

 Yes

42

33.6

 Unknown

1

0.8

Starting dose of afatinib once daily (OD)

 40 mg

62

49.6

 30 mg

61

48.8

 20 mg

1

0.8

 Unknown

1

0.8

aE746_A750del; E746_A750delinsIP; E746_A750delinsQP; E746_A750delinsVP; E746_T751delinsV; E746_S752delinsV; E746_P753delinsVS; L747_A750delinsP; L747_T751del; L747_P753delinsS; NOS

bE697Q; A763_Y764insFQEA; Double mutation; Unknown NSCLC Non-small cell lung cancer, NOS Not otherwise specified

The corrected Table 1 is presented below.

Reference

  1. 1.
    Tan, et al. Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases. 2018, 2018;18:1198.  https://doi.org/10.1186/s12885-018-5110-2.

Copyright information

© The Author(s). 2018

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors and Affiliations

  • Wan-Ling Tan
    • 1
  • Quan Sing Ng
    • 1
  • Cindy Lim
    • 2
  • Eng Huat Tan
    • 1
  • Chee Keong Toh
    • 1
  • Mei-Kim Ang
    • 1
  • Ravindran Kanesvaran
    • 1
  • Amit Jain
    • 1
  • Daniel S. W. Tan
    • 1
    • 3
  • Darren Wan-Teck Lim
    • 1
    • 4
    Email author
  1. 1.Division of Medical OncologyNational Cancer Centre SingaporeSingaporeSingapore
  2. 2.Clinical Trials & Epidemiological Sciences, National Cancer Centre SingaporeSingaporeSingapore
  3. 3.Genome Institute of Singapore, A*STARSingaporeSingapore
  4. 4.Institute of Molecular and Cell Biology, A*STARSingaporeSingapore

Personalised recommendations